Shares of SeQuent Scientific Ltd. surged more than 10% after the company announced that the National Company Law Tribunal (NCLT) has approved its merger with Viyash Lifesciences Private Limited and its group companies.
At 9:07 AM on November 19, the stock was trading at ₹256.44, up 10.95%, reflecting strong investor sentiment following the announcement.
NCLT approves SeQuent–Viyash merger
In a joint statement, SeQuent and Viyash said the NCLT has allowed the petition and approved the proposed Scheme of Merger. The development marks a major milestone for the companies, setting the stage for what they described as a “fundamental transformation to leapfrog into the next orbit of the global animal health market.”
The merged entity will bring together strengths from both organisations, creating India’s largest animal health player with a significantly expanded global footprint.
Financial scale of the combined entity
As per the companies’ disclosure:
-
Aggregate H1 FY26 revenue: ₹16.5 billion
-
Aggregate H1 FY26 EBITDA: ₹3.2 billion
-
Net Debt to EBITDA ratio: 0.7x
The scale and balance sheet strength highlight the merged entity’s improved competitiveness in the global animal health industry.
